TDI-011536 is primarily investigated for its potential in cancer therapy, particularly in targeting specific pathways involved in tumor growth and survival. It functions as an inhibitor of certain kinases that play a critical role in cell proliferation and survival, making it a promising candidate for treating various cancers. Research has focused on its ability to disrupt signaling pathways that are often dysregulated in cancer cells, thereby inhibiting their growth and promoting apoptosis. Additionally, TDI-011536 is being studied for its potential in combination therapies, where it may enhance the efficacy of other anticancer drugs. Its application extends to preclinical studies aimed at understanding its mechanism of action and optimizing its therapeutic potential.